{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:23:20Z","timestamp":1791210200914,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"am","delay-in-days":298,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ejmech.2022.114468","type":"journal-article","created":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T06:47:45Z","timestamp":1653115665000},"page":"114468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Development of sulfonamide-based NLRP3 inhibitors: Further modifications and optimization through structure-activity relationship studies"],"prefix":"10.1016","volume":"238","author":[{"given":"Yiming","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hallie","family":"Blevins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunqing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savannah","family":"Biby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9732-5925","authenticated-orcid":false,"given":"Shijun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114468_bib1","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.cell.2014.04.007","article-title":"Mechanisms and functions of inflammasomes","volume":"157","author":"Lamkanfi","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.114468_bib2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev-cellbio-101011-155745","article-title":"Inflammasomes and their roles in health and disease","volume":"28","author":"Lamkanfi","year":"2012","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2022.114468_bib3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/ni.2237","article-title":"Regulation of inflammasom signaling","volume":"13","author":"Rathinam","year":"2012","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejmech.2022.114468_bib4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/febs.13133","article-title":"Structural mechanisms of inflammasome assembly","volume":"282","author":"Lu","year":"2015","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2022.114468_bib5","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.cell.2010.01.040","article-title":"The inflammasomes","volume":"140","author":"Schroder","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.114468_bib6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2022.114468_bib7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nature13683","article-title":"Inflammatory caspases are innate immune receptors for intracellular LPS","volume":"514","author":"Shi","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114468_bib8","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1172\/JCI98322","article-title":"Confounding role of tumor necrosis factor in cryopyrin-associated periodic syndromes","volume":"127","author":"Banoth","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejmech.2022.114468_bib9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/ng756","article-title":"Mutation of a new gene encoding a putative pyrin- like protein causes familial cold autoinflammatory syndrome and Muckle- Wells syndrome","volume":"29","author":"Hoffman","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2022.114468_bib10","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1002\/art.10509","article-title":"Association of mutations in the NALP3\/CIAS1\/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis","volume":"46","author":"Aganna","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2022.114468_bib11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fimmu.2013.00050","article-title":"Mechanisms of disease: inflammasome activation and the development of type 2 diabetes","volume":"4","author":"Grant","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2022.114468_bib12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.2279","article-title":"The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance","volume":"17","author":"Vandanmagsar","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2022.114468_bib13","doi-asserted-by":"crossref","first-page":"443","DOI":"10.5551\/jat.RV17001","article-title":"Role of NLRP3 inflammasomes in atherosclerosis","volume":"24","author":"Karasawa","year":"2017","journal-title":"J. Atherosclerosis Thromb."},{"key":"10.1016\/j.ejmech.2022.114468_bib14","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nature11729","article-title":"NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP\/PS1 mice","volume":"493","author":"Heneka","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114468_bib15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.nbd.2018.02.016","article-title":"NLRP3-dependent synaptic plasticity deficit in an Alzheimer's disease amyloidosis model in vivo","volume":"114","author":"Qi","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejmech.2022.114468_bib16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41418-018-0124-5","article-title":"MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration","volume":"26","author":"Lee","year":"2019","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2022.114468_bib17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/bpa.12477","article-title":"Inflammasome activation in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE)","volume":"27","author":"Barclay","year":"2017","journal-title":"Brain Pathol."},{"key":"10.1016\/j.ejmech.2022.114468_bib18","doi-asserted-by":"crossref","first-page":"111822","DOI":"10.1016\/j.ejmech.2019.111822","article-title":"Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases","volume":"185","author":"Zhang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114468_bib19","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2022.114468_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114338","article-title":"Synthesis and pharmacological validation of fluorescent diarylsulfonylurea analogues as NLRP3 inhibitors and imaging probes","volume":"237","author":"Zhao","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114468_bib21","doi-asserted-by":"crossref","unstructured":"P. Narros-Fern\u00e1ndez, M. Chioua, S.A. Petcu, D. Diez-Iriepa, L. Cerrada-G\u00e1lvez, C. Decouty-P\u00e9rez, A. Palomino-Antol\u00edn, E. Ramos, V. Farr\u00e9-Alins, A. B. L\u00f3pez-Rodr\u00edguez, A. Romero, J. Marco-Contelles, J. Egea, Synthesis and pharmacological evaluation of new N-sulfonylureas as NLRP3 inflammasome inhibitors: identification of a hit compound to treat gout. J. Med. Chem.. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c00149.","DOI":"10.1021\/acs.jmedchem.2c00149"},{"key":"10.1016\/j.ejmech.2022.114468_bib22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1083\/jcb.200903124","article-title":"Glyburide inhibits the Cryopyrin\/Nalp3 inflammasome","volume":"187","author":"Lamkanfi","year":"2009","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejmech.2022.114468_bib23","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1021\/acs.jmedchem.6b01624","article-title":"Development of an acrylate derivative targeting the NLRP3 inflammasome for the treatment of inflammatory bowel disease","volume":"60","author":"Cocco","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114468_bib24","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1084\/jem.20171419","article-title":"Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders","volume":"214","author":"Jiang","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2022.114468_bib25","doi-asserted-by":"crossref","first-page":"e8689","DOI":"10.15252\/emmm.201708689","article-title":"Tranilast directly targets NLRP3 to treat inflammasome-driven diseases","volume":"10","author":"Huang","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ejmech.2022.114468_bib26","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1074\/jbc.M113.515080","article-title":"3,4-methylenedioxy-beta-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome","volume":"289","author":"He","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114468_bib27","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1073\/pnas.1716095115","article-title":"OLT1177, a \u03b2-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation","volume":"115","author":"Marchetti","year":"2018","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.ejmech.2022.114468_bib28","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1021\/acs.jmedchem.8b00733","article-title":"Structural insights of benzenesulfonamide analogues as NLRP3 inflammasome inhibitors: design, synthesis, and biological characterization","volume":"61","author":"Fulp","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114468_bib29","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1021\/acschemneuro.7b00124","article-title":"Development and characterization of a hydroxyl-sulfonamide analogue, 5-chloro-N-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a novel NLRP3 inflammasome inhibitor for potential treatment of multiple sclerosis","volume":"8","author":"Guo","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2022.114468_bib30","doi-asserted-by":"crossref","first-page":"9718","DOI":"10.1021\/acs.jmedchem.9b01155","article-title":"Discovery of second-generation NLRP3 inflammasome inhibitors: design, synthesis, and biological characterization","volume":"62","author":"Jiang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114468_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FJC.0000000000000247","article-title":"Pharmacologic inhibition of the NLRP3 inflammasome preserves cardiac function after ischemic and nonischemic injury in the mouse","volume":"66","author":"Marchetti","year":"2015","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114468_bib32","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ijcard.2016.02.043","article-title":"Inhibition of the NLRP3 inflammasome limits the inflammatory injury following myocardial ischemia-reperfusion in the mouse","volume":"209","author":"Toldo","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ejmech.2022.114468_bib33","doi-asserted-by":"crossref","first-page":"334","DOI":"10.4049\/jimmunol.1202737","article-title":"TLR agonists stimulate nlrp3-dependent IL-1\u03b2 production independently of the purinergic P2X7 receptor in dendritic cells and in vivo","volume":"190","author":"He","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2022.114468_bib34","doi-asserted-by":"crossref","first-page":"127777","DOI":"10.1016\/j.bmcl.2021.127777","article-title":"Discovery of carbon-11 labeled sulfonamide derivative: a PET tracer for imaging brain NLRP3 inflammasome","volume":"34","author":"Xu","year":"2021","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2022.114468_bib35","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00228-003-0643-x","article-title":"Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development","volume":"59","author":"Bergstr\u00f6m","year":"2003","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114468_bib36","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2165\/00003088-200241080-00003","article-title":"Pharmacokinetic imaging: a noninvasive method for determining drug distribution and action","volume":"41","author":"Fischman","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2022.114468_bib37","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1021\/acscentsci.7b00195","article-title":"18F-Deoxyfluorination of phenols via Ru \u03c0-complexes","volume":"3","author":"Beyzavi","year":"2017","journal-title":"ACS Cent. Sci."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422003701?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422003701?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T14:13:01Z","timestamp":1728396781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422003701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":37,"alternative-id":["S0223523422003701"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114468","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of sulfonamide-based NLRP3 inhibitors: Further modifications and optimization through structure-activity relationship studies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114468","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114468"}}